Evidence map›Paper›PMID 20416090›Full record

ArticleBMC microbiology2010

Azithromycin effectiveness against intracellular infections of Francisella.

Saira Ahmad, Lyman Hunter, Aiping Qin, Barbara J Mann, Monique L van Hoek

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2025
    Guideline
  2. Review
  3. Review
  4. Review
  5. Article
  6. Genetic Determinants of Antibiotic Resistance inFrontiers in microbiology · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Frontiers in cellular and infection microbiology · 2020
    Article
  11. Serendipitous Treatment of Tularemia in Pregnancy.Open forum infectious diseases · 2019
    Article
  12. Article
  13. Article
  14. AR-13, a Celecoxib Derivative, Directly KillsFrontiers in microbiology · 2017
    Article
  15. The orange spotted cockroach (Proceedings of the West Virginia Academy of Science · 2017
    Article
  16. Frontiers in cellular and infection microbiology · 2017
    Review
  17. Article
  18. Review
  19. Potentiation ofMedChemComm · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Saira AhmadDepartment of Molecular and Microbiology, National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, VA 20120, USA.
Lyman Hunter
Aiping Qin
Barbara J Mann
Monique L van Hoek
George Mason University · USUniversity of Virginia · USInova Fairfax Hospital · US

Funding

UVA Digestive Health Research CenterP30DK067629 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI COMINELLI, FABIO · 2004 to 2008
$5.6M
NIDDK NIH HHS P30 DK067629
6 · The paper itself

Abstract

backgroundMacrolide antibiotics are commonly administered for bacterial respiratory illnesses. Azithromycin (Az) is especially noted for extremely high intracellular concentrations achieved within macrophages which is far greater than the serum concentration. Clinical strains of Type B Francisella (F.) tularensis have been reported to be resistant to Az, however our laboratory Francisella strains were found to be sensitive. We hypothesized that different strains/species of Francisella (including Type A) may have different susceptibilities to Az, a widely used and well-tolerated antibiotic.

resultsIn vitro susceptibility testing of Az confirmed that F. tularensis subsp. holarctica Live Vaccine Strain (LVS) (Type B) was not sensitive while F. philomiragia, F. novicida, and Type A F. tularensis (NIH B38 and Schu S4 strain) were susceptible. In J774A.1 mouse macrophage cells infected with F. philomiragia, F. novicida, and F. tularensis LVS, 5 microg/ml Az applied extracellularly eliminated intracellular Francisella infections. A concentration of 25 microg/ml Az was required for Francisella-infected A549 human lung epithelial cells, suggesting that macrophages are more effective at concentrating Az than epithelial cells. Mutants of RND efflux components (tolC and ftlC) in F. novicida demonstrated less sensitivity to Az by MIC than the parental strain, but the tolC disc-inhibition assay demonstrated increased sensitivity, indicating a complex role for the outer-membrane transporter. Mutants of acrA and acrB mutants were less sensitive to Az than the parental strain, suggesting that AcrAB is not critical for the efflux of Az in F. novicida. In contrast, F. tularensis Schu S4 mutants DeltaacrB and DeltaacrA were more sensitive than the parental strain, indicating that the AcrAB may be important for Az efflux in F. tularensis Schu S4. F. novicida LPS O-antigen mutants (wbtN, wbtE, wbtQ and wbtA) were found to be less sensitive in vitro to Az compared to the wild-type. Az treatment prolonged the survival of Galleria (G.) mellonella infected with Francisella.

conclusionThese studies demonstrate that Type A Francisella strains, as well as F. novicida and F. philomiragia, are sensitive to Az in vitro. Francisella LPS and the RND efflux pump may play a role in Az sensitivity. Az also has antimicrobial activity against intracellular Francisella, suggesting that the intracellular concentration of Az is high enough to be effective against multiple strains/species of Francisella, especially in macrophages. Az treatment prolonged survival an in vivo model of Francisella-infection.

Indexed as

AnimalsAnti-Bacterial AgentsAzithromycinCell LineEpithelial CellsFrancisellaHumansLepidopteraMacrophagesMiceMicrobial Sensitivity TestsMicrobial ViabilitySurvival AnalysisAnti-Bacterial AgentsAzithromycin

Identifiers

PMID20416090
PMCPMC2881020
OpenAlexW2046161765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.